The Clinical Trials Office (CTO) was organized and implemented as a reflection of the Center leadership's commitment to increasing institutional and multimodality research, and to address the increasingly complex regulatory environment associated with clinical trials. Richard Wheeler, M.D., was recruited in late 1999 to establish and supervise the CTO, which has been supported primarily with institutional funds. The CTO is located on the second floor of HCI adjacent to the outpatient clinics and clinical faculty offices. It functions as a central administrative office for the implementation and conduct of internally and externally funded adult oncology studies. As a proposed clinical shared resource, the CTO is directly responsible to the Clinical Research Executive Committee (CREC). The CTO is administratively responsible for supervising protocol initiation and maintenance, quality control, regulatory compliance, budget development, and protocol educational activities. The CTO currently has 11 study coordinators who assist investigators in patient enrollment, study compliance, and data management. The specific objectives of the CTO are: . To support cancer center investigators with centralized protocol development, initiation, and management. . To assist in the preparation of protocols to the IRB, Clinical Cancer Investigations Committee (CCIC), and other review committees, as required by federal and University of Utah policy. . To process all regulatory documents, including submission of protocol amendments, revisions, adverse events, and annual renewals to the IRB, CCIC, and other applicable regulatory committees. . To negotiate budgets and contracts with study sponsors and the University of Utah Office of Sponsored Projects. . To assist investigators in the enrollment of study subjects. . To screen new patients for protocol eligibility. . To provide quality data to sponsors and ensure study compliance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-18
Application #
7063437
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
18
Fiscal Year
2005
Total Cost
$26,379
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Fleming, Aaron M; Zhu, Judy; Ding, Yun et al. (2018) Human DNA Repair Genes Possess Potential G-Quadruplex Sequences in Their Promoters and 5'-Untranslated Regions. Biochemistry 57:991-1002
Hellwig, Sabine; Nix, David A; Gligorich, Keith M et al. (2018) Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One 13:e0197333
Martin, Christopher; Leiser, Claire L; O'Neil, Brock et al. (2018) Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst 110:527-533
Mollaoglu, Gurkan; Jones, Alex; Wait, Sarah J et al. (2018) The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity 49:764-779.e9
Sorenson, Reed S; Deshotel, Malia J; Johnson, Katrina et al. (2018) Arabidopsis mRNA decay landscape arises from specialized RNA decay substrates, decapping-mediated feedback, and redundancy. Proc Natl Acad Sci U S A 115:E1485-E1494
Polanco, Edward R; Western, Nicholas; Zangle, Thomas A (2018) Fabrication of Refractive-index-matched Devices for Biomedical Microfluidics. J Vis Exp :
Camolotto, Soledad A; Pattabiraman, Shrivatsav; Mosbruger, Timothy L et al. (2018) FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife 7:
Nevala-Plagemann, Christopher; Francis, Samual; Cavalieri, Courtney et al. (2018) Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open 3:e000386
Li, Lian; Yang, Jiyuan; Wang, Jiawei et al. (2018) Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics. ACS Nano 12:3658-3670
Wu, Yelena P; Nagelhout, Elizabeth; Aspinwall, Lisa G et al. (2018) A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns 101:452-459

Showing the most recent 10 out of 1193 publications